Clinical trials: Clopidogrel, completed
Healthy
Pharmacodynamics of CGT 2168 Compared With Plavix®
CG106 is a Phase I open-label, randomized, multiple-dose, two-way crossover study to characterize the pharmacodynamics and pharmacokinetics of the investigational fixed-dose combination product CGT 2168 (clopidogrel, 75 mg and…
- Trial name
- NCT00620802
- Testing
- CGT-2168, Plavix
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cogentus Pharmaceuticals
Ischemic Stroke
Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China
The SAMMPRIS suggested that aggressive treatment was superior to intravascular stenting in patients with severe symptomatic intracranial atherosclerotic stenosis (ICAS) due to high complication rate in patients in stenting group.
- Trial name
- NCT01968122
- Testing
- intravascular stent therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhongrong Miao
Metabolic Syndrome x
PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome
The purpose of this study is to examine the effects of clopidogrel compared to placebo on markers of inflammation in subjects with metabolic syndrome who are receiving background therapy including low dose aspirin.
- Trial name
- NCT00296803
- Testing
- clopidogrel
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Sanofi
Platelet Aggregation Inhibitors, Coronary Heart Disease
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or clopidogrel. However, studies have shown that not all people respond to these medications.
- Trial name
- NCT00799396
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Stable Coronary Artery Disease, Acute Coronary Syndrome
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
The objective of the RAPID GENE study is to evaluate the feasibility, efficacy and safety of a pharmacogenomic approach to anti-platelet therapy following coronary artery stenting using a CYP2C19*2 point-of-care genetic test.
- Conditions
- Stable Coronary Artery Disease, Acute Coronary Syndrome, Percutaneous Coronary Intervention
- Trial name
- RAPID GENE (NCT01184300)
- Testing
- Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Cardiovascular Disease, Overweight
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- PLATO-dose (NCT01509365)
- Testing
- clopidogrel
- Where
- Tunisia
- Volunteers
- 116 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Unruptured Intracranial Aneurysm, Stents
Application of Platelet Function Test in Prevention of Ischemic Events After Stent Placement in Intracranial Aneurysms
This study was designed to identify high platelet reactivity (HPR) who might have in-stent thrombosis in unruptured aneurysm with intracranial stent placement with light transmittance platelet aggregometry (LTA).
- Conditions
- Unruptured Intracranial Aneurysm, Stents, Antiplatelet Drugs
- Trial name
- APISIA Trail (NCT03989557)
- Testing
- Aspirin and clopidogrel/Ticagrelor, Light transmittance aggregometry
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Beijing Neurosurgical Institute
Myocardial Infarction, STEMI
Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI
Acute myocardial infarction is generally caused by a thrombotic occlusion of coronary arteries. Primary aim of early therapy is a fast and complete reperfusion of the infarcted myocardium.
- Trial name
- ETAMI (NCT01327534)
- Testing
- Prasugrel, Clopidogrel
- Where
- 3 sites in France, Germany
- Volunteers
- 63 people
- Sponsor
- Stiftung Institut fuer Herzinfarktforschung
Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).
The use of dual antiplatelet therapy is considered standard of care in patients post percutaneous coronary intervention (PCI) with stenting.
- Trial name
- NCT01109784
- Testing
- prasugrel, clopidogrel
- Where
- Greece
- Volunteers
- 70 people
- Sponsor
- University of Patras
Pleural Effusion, Thoracic Effusion
The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants
To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.
- Trial name
- NCT03535883
- Testing
- Novel Oral Anti-Coagulants
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- Yale University
Acute Coronary Syndrome
Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)
This study demonstrates the effect of generic clopidogrel bisulfate (Plavitor®) in comparison with the original clopidogrel bisulfate (Plavix®) in patients with acute coronary syndrome.
- Trial name
- NCT02060786
- Testing
- generic clopidogrel (Plavitor® ), original clopidogrel (Plavix® )
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Ajou University School of Medicine
End-Stage Renal Disease, Kidney Failure, Chronic
MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)
MK-2060 is being developed for prevention of thrombotic complications in end-stage renal disease (ESRD). The purpose of this study is to conduct a preliminary evaluation of the safety and tolerability of MK-2060 treatment in…
- Trial name
- NCT05335005
- Testing
- MK-2060
- Where
- 3 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease, Peripheral Arterial Disease
Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Conditions
- Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
- Trial name
- NCT03718429
- Testing
- Rivaroxaban 2.5 mg Tablet
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- University of Florida
Atrial Fibrillation, Percutaneous Coronary Intervention
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate…
- Trial name
- NCT02164864
- Testing
- Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin
- Where
- 421 sites in United States, Argentina and 39 more
- Volunteers
- 2,725 people
- Sponsor
- Boehringer Ingelheim
Platelet Dysfunction, Von Willebrand Diseases
Clinical Performance Evaluation of T-TAS 01 PL Chip
This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth.
- Conditions
- Platelet Dysfunction, Von Willebrand Diseases, Healthy, Congenital Platelets Abnormality
- Trial name
- NCT03621020
- Testing
- T-TAS 01 PL Chip, PFA-100 Col/Epi and Col/ADP
- Where
- 6 sites in United States, France
- Volunteers
- 307 people, healthy volunteers welcome
- Sponsor
- Hikari Dx, Inc.
Acute Ischemic Stroke
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy…
- Trial name
- NCT04809818
- Testing
- LT3001 drug product, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Healthy
Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects
Primary objective: Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given either alone in the morning, or in association with…
- Trial name
- NCT01129388
- Testing
- clopidogrel, omeprazole
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sanofi
Ischemic Stroke, Transient Ischemic Attack
Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke
This is a randomized, controlled, active comparator arm, outcome assessor blind, parallel group design on 90 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is assess the…
- Trial name
- TACAMINIS (NCT04738097)
- Testing
- Ticagrelor 90mg, Clopidogrel 75 mg
- Where
- 2 sites in Iran
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences
Acute Coronary Syndrome
Platelet Aggregation During the Shift From Clopidogrel to Ticagrelor
Antiplatelet therapy with ticagrelor is currently indicated for treatment of patients presenting with acute coronary syndrome. Such therapy is started with the administration of a loading dose in patients which are not yet under…
- Trial name
- SHIFT-OVER (NCT01795820)
- Testing
- loading with Ticagrelor, no loading with Ticagrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University Magna Graecia
Antiplatelet Aggregation
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
The purpose of the study is to look at the biomarkers of inflammation and platelet activation in patients with drug eluting stents implanted approximately 12 months ago on aspirin and statin, for a 4-week period after the routine…
- Trial name
- DECADES (NCT00493779)
- Testing
- Blood Collection
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- Bristol-Myers Squibb